Blog | BioInformant

Avalon GloboCare Acquires Leading Beijing Exosome Technology Company

December 3, 2017 By Cade Hildreth, Founder & President Leave a Comment

Avalon Forms Subsidiary U.S. Company, GenExosome Technologies Inc., for the Global Advancement of Exosome Technology for Diagnosis and Treatment of Diseases

FREEHOLD, NJ–(October 30, 2017) – Avalon GloboCare Corp. (OTCQB: AVCO), a leading global developer of cell-based technologies, announced today that its majority-owned subsidiary GenExosome Technologies Inc. (GenExosome) acquired 100% of the outstanding capital stock of Beijing Jieteng (Beijing GenExosome) Biotech Co. Ltd. Concurrently, GenExosome entered into and closed an Asset Purchase Agreement with Dr. Yu Zhou, CEO of GenExosome Beijing, pursuant to which GenExosome acquired all assets, including all intellectual property, patents and patent applications held by Dr. Zhou pertaining to the business of researching, developing and commercializing exosome technologies. Additional details of the transaction are available in the Company’s form 8-K filed with the Securities & Exchange Commission on October 27, 2017, and is available at www.sec.gov.
[Read more…]

Pluristem Granted Key U.S. Patent for Skeletal Muscle Regeneration – a Meaningful Asset Ahead of Upcoming Phase III Femoral Neck Fracture Study

November 27, 2017 By Cade Hildreth, Founder & President Leave a Comment

Patent relates to the use of Mesenchymal Stem Cells (MSCs) for muscle regeneration following muscle injury
Pivotal Phase III study to take place in U.S. and Europe to support recovery from hip fracture

HAIFA, Israel, Nov. 22, 2017 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a patent titled, “Skeletal muscle regeneration using mesenchymal system cells.” This key patent, which has already been granted in Europe, Hong Kong and Israel, addresses the use of MSCs for skeletal muscle regeneration used either directly after, or shortly after, post-surgical muscle injury.

The Company received positive feedback from the U.S. Food and Drug Administration (FDA) and the European Medicine Agency (EMA) for the proposed study design and endpoints of its Phase III trial for the treatment of muscle recovery following arthroplasty for hip fracture. This planned study was recently awarded an $8.7 million grant by the Horizon 2020 program, the European Union’s largest research and innovation program. If successful, Pluristem plans to use the study results to achieve marketing approval in both the U.S. and Europe. [Read more…]

Dubai First to Launch Innovative Stem Cell Therapy for Joint Disease

November 21, 2017 By Cade Hildreth, Founder & President Leave a Comment

UAE residents will no longer need to travel abroad to receive stem cell therapy for joint disease

Dubai, United Arab Emirates, November 21 2017 – Bioscience Clinic FZ LLC located in Dubai Healthcare City is pleased to launch to its latest innovative stem cells therapy for treatment of joint disease. Established since 2012, Bioscience Clinic is Dubai’s first and most advanced clinic to use stem cells taken from adipose tissue in a variety of clinical applications. Its latest therapy was first introduced in Europe by Bioscience Institute, a Bioscience Clinic sister company. [Read more…]

ISCT Webinar on Cell and Gene Therapy (CGT) Products in Japan

November 18, 2017 By Cade Hildreth, Founder & President Leave a Comment

Have you heard of the recent regulatory changes surrounding cell and gene therapy (CGT) products in Japan?

These changes have greatly increased the interest in taking CGT clinical programs to Japan from development through commercialization. ISCT (International Society for Cellular Therapy) and FIRM (Forum for Innovative Regenerative Medicine) have created a partnership to facilitate the entry and development of future CGT products in Japan.

Robert Preti, PhD (General Manager of Hitachi Chemical’s Regenerative Medicine Business Sector) and Kazuchika Furuishi, PhD (Deputy General Manager) are joining a leading Japanese management consultant (Colin Novick) to discuss the challenges to consider and examples of solutions for successfully taking your clinical cell or gene therapy program to Japan.

On Wednesday, December 6, the webinar will explore the attractive regulatory changes in Japan, as well as:

Increased offshore filing activity
Challenges to consider
Successful CGT programs brought to Japan

Register now for the Hitachi Chemical Advanced Therapeutics Solutions, LLC sponsored webinar and learn from experts:

http://www.celltherapysociety.org/?page=wbnr_BMI

[Read more…]

Cynata Therapeutics Releases Investor Presentation Featuring Operational Progress

November 17, 2017 By Cade Hildreth, Founder & President Leave a Comment

Melbourne, Australia; 15 November 2017: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), is pleased to release a new investor presentation to be presented at a series of upcoming institutional investor meetings.

Paul Wotton (Cynata Chairman) and Ross Macdonald (Cynata CEO) will be meeting with a series of new and existing institutional investors prior to the upcoming AGM on November 17.

Cynata Therapeutics provides investors with excellent exposure to a rapidly growing regenerative medicine and stem cell sector via its patented CymerusTM technology, a platform able to manufacture mesenchymal stem cells (MSCs) at a commercial scale. The new investor presentation highlights Cynata Therapeutics’ compelling investment case and provides information about the Company’s progress. [Read more…]